Why Novanta (NOVT) Is Up 16.7% After Q2 Results And Its Largest Medical Acquisition

• In the past week, Novanta Inc. reported second-quarter 2026 results showing sales of US$265.81 million and net income of US$12.54 million, alongside higher earnings per share versus a year earlier and updated guidance that now includes its newly closed Riverpoint Medical acquisition.
• The Riverpoint Medical deal, Novanta’s largest acquisition to date, meaningfully increases its exposure to medical end markets and recurring consumables, potentially reshaping the company’s business mix and earnings profile.
• With the Riverpoint acquisition now closed, we’ll examine how this expanded medical footprint could influence Novanta’s acquisition-led investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Novanta Investment Narrative Recap

To own Novanta, you need to believe in its ability to compound through automation and medical technology while using acquisitions to offset uneven organic demand. The latest Q2 beat and raised 2026 revenue guidance, now including Riverpoint Medical, supports that acquisition-led growth catalyst, but also raises the near term execution risk around integration, manufacturing restructuring and keeping margins on track. If those pieces hold together, the recent news does not materially change the core long term thesis.

The most relevant announcement is Novanta’s updated 2026 guidance, which now assumes Riverpoint Medical’s contribution and points to GAAP revenue of US$1,130 million to US$1,140 million. That higher run rate, together with stronger Q2 profitability, reinforces the catalyst of a larger, more recurring medical consumables base, but it also leans more heavily on successful integration and on the company’s ability to manage tariff related regionalization without eroding the earnings progress investors are watching closely.

Yet behind the headline growth, investors should be aware that ongoing trade disruptions and manufacturing regionalization could still...

Read the full narrative on Novanta (it's free!)

Novanta's narrative projects $1.7 billion revenue and $76.4 million earnings by 2029. This requires 17.1% yearly revenue growth and a roughly $14.6 million earnings increase from $61.8 million today.

Uncover how Novanta's forecasts yield a $182.00 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community range widely from about US$44 to US$195, underlining how far apart individual views can be. Against that backdrop, Novanta’s reliance on acquisitions to drive growth, highlighted again by the Riverpoint Medical deal, gives you a clear reason to compare several of those viewpoints before deciding what the stock’s future performance could look like.

Explore 3 other fair value estimates on Novanta - why the stock might be worth as much as 17% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novanta research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novanta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novanta's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 52 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com